On the one hand: trastuzumab inhibits tumor cell growth and differentiation by binding to the HER2 extracellular structural domain and inhibiting the MAPK and PI3K/Akt pathways (Junttila et al., 2009). The gene discussed is ERBB2; the disease is neoplasm.